Pfizer, BioNTech find updated COVID booster protects against Omicron in trial
/cloudfront-us-east-2.images.arcpublishing.com/reuters/I6XWR6AYYFLQ3NGU2WCG67F7IY.jpg)
Pfizer and its German partner BioNTech said their COVID-19 vaccine booster, adapted for the BA.4 and the BA.5 subvariants of Omicron, generated a strong immune response and was well-tolerated in testing on humans.
Thursday, October 13, 2022 at 2:38 pm